Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
HCV Advocate

Wednesday, March 21, 2012

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

Prolonged therapy with antiretroviral regimens containing tenofovir is associated with a decline in hepatitis B surface antigen (HBsAg) levels in people coinfected with HIV and hepatitis B virus (HBV), according to a report presented by Dutch researchers at the 19th Conference on Retroviruses and Opportunistic Infections on Tuesday, March 6, in Seattle.

Loss of HBsAg is the ultimate chronic HBV infection treatment goal, as it signals that the immune system has ramped up and gained control of HBV replication. Among people with chronic HBV infection who experience a spontaneous loss in HBsAg, rates of cirrhosis and liver cancer are significantly lower than those who remain positive for the antigen, considered to be one of the most important markers of active infection.

Read more....

No comments:

Post a Comment